Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADVANCE Phase III trial of Essentiale liquid versus capsules in chronic liver disease
2025-521678-32-00Phase 3Authorised
- Sponsor
- Opella
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of polyene phosphatidylcholine in metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-associated steatohepatitis (MASH), alcoholic liver disease (ALD) and 1 more (2 arms), sponsored by Opella. Primary endpoint: Change in overall symptoms by Global Overall Symptom score. Planned start Mar 2026; status: authorised.
02
Drugs
polyene phosphatidylcholine
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)metabolic dysfunction-associated steatohepatitis (MASH)alcoholic liver disease (ALD)Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2025-521678-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521678-32-00.